TLDR Baricitinib helps alopecia areata and may improve psoriasis, but its effect on psoriatic arthritis is unclear.
This study assessed baricitinib's efficacy and safety in 5 patients with severe alopecia areata (AA) and coexisting psoriasis and/or psoriatic arthritis (PsA) over 52 weeks. One patient achieved complete AA remission, and two others showed significant improvement, while psoriasis remained stable. However, one PsA patient experienced worsening symptoms, leading to treatment discontinuation. The findings suggest baricitinib is effective for AA and may benefit psoriasis, but it may not be suitable for PsA. The study's small sample size limits generalizability, indicating a need for further research to understand baricitinib's role in treating multiple immune-mediated diseases.
5 citations
,
December 2023 in “Journal of the European Academy of Dermatology and Venereology” 
6 citations
,
May 2023 in “Drugs” Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.
9 citations
,
January 2023 in “Dermatology and therapy” A 14-year-old girl with severe hair loss regrew her hair using upadacitinib.
14 citations
,
March 2022 in “Journal of inflammation research” Baricitinib shows promise as a new treatment for certain skin conditions like alopecia areata.
144 citations
,
November 2020 in “Frontiers in immunology” Targeting the IL-23/IL-17 pathway effectively treats several inflammatory skin diseases.
3 citations
,
August 2020 in “Case Reports in Dermatology” Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.
176 citations
,
August 2015 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Alopecia areata involves immune activation in the scalp, suggesting treatments targeting TH1, TH2, and IL-23 pathways.
